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Inherited retinal degenerations (IRDs) are a genotypically and phenotypically diverse
group of conditions. Great strides have been made toward identifying the genetic
basis for these conditions over the last 30 years—more than 270 different genes
involved in syndromic and nonsyndromic forms of retinal dystrophies have now been
identified. The identification of these genes and the improvement of clinical labora-
tory techniques have led to the identification of the genetic basis of disease in
56–76% of patients with IRDs through next generation sequencing and copy number
variant analysis. Genetic testing is an essential part of clinical care for patients
affected with IRDs and is required to confirm the diagnosis, understand the inheri-
tance of the condition, and determine eligibility for gene-specific treatments or clini-
cal trials. Despite the success achieved in determining the genetic cause of these
conditions, several challenges remain, which must be considered when providing
genetic testing and genetic counseling to patients. For this reason, an integrated
team of ophthalmic and genetic clinicians who are familiar with these challenges is
necessary to provide optimal comprehensive care to these patients.
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1 | INTRODUCTION
Inherited retinal degenerations (IRDs) are a phenotypically and geno-
typically diverse group of conditions that cause vision loss due to a
loss of function of retinal photoreceptor cells. Presenting symptoms
may be poor peripheral and/or night vision, as seen in retinitis
pigmentosa (RP); poor central vision, as seen in Stargardt disease; or
early onset nystagmus, as seen in Leber congenital amaurosis (LCA),
and achromatopsia. These conditions may present as isolated ophthal-
mic findings or in the context of a syndrome. The most common IRD
is RP or rod-cone dystrophy (RCD), with an incidence of 1/3,500
(Haim, 2002). While individually each of these IRDs is rare, collectively
it is estimated that there are more than 140,000–200,000 people
affected with retinal dystrophies in the United States (Daiger, Sulli-
van, & Bowne, 2013; Stone et al., 2017). A patient presenting to a
genetics clinic may have an existing diagnosis of a macular dystrophy,
cone-rod dystrophy, or RCD. These are general categories of IRDs,
but also frequently overlapping in phenotype. By ordering genetic
testing on these patients through a broad inherited retinal dystrophy
panel, a more specific diagnosis, information on prognosis, additional
information on inheritance of the condition, and potential eligibility
for clinical trials may be obtained.
Part of the complexity of these conditions is that multiple
genotype–phenotype associations have been established for them. A
single phenotype may arise from a variety of different genetic causes,
and, conversely, a single gene may be associated with multiple pheno-
types (Berger, Kloeckener-Gruissem, & Neidhardt, 2010). The PRPH2
gene is a prime example of this phenotypic heterogeneity: pathogenic
variants in this gene may be associated with macular disease such as
pattern dystrophy, butterfly macular dystrophy, or vitelliform dystro-
phy, or it may cause peripheral retinal degeneration such as RP (Leroy,
Kailasanathan, De Laey, Black, & Manson, 2007). This variability may
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even be seen within the same family. In other cases, pathogenic vari-
ants in the same gene may cause some patients to be affected with
syndromic disease and others with nonsyndromic disease. The USH2A
gene, for example, is the most common cause of nonsyndromic RP
and also the most common cause of Usher Syndrome Type II
(Pontikos et al., 2020; Stone et al., 2017).
The first IRD-associated gene (RHO) was identified in 1990 (Dryja
et al., 1990). At that time, it was anticipated that a small number of
genes would be found to cause IRDs. However, more than 270 IRD-
related genes have now been identified, including 90 for non-
syndromic RP alone, as shown in Figure 1 (https://sph.uth.edu/
retnet/). While disease-causing variants are much more prevalent in
some of these genes are than in others, there is no single genetic
cause that is responsible for the majority of these patients. A large
genotyping study of over 3,000 families affected with IRDs in the
United Kingdom identified molecular diagnoses due to pathogenic
variants in 135 different genes; however, 70% of families had patho-
genic variants in the most common 20 genes (Pontikos et al., 2020).
This study and a similar study in the United States found that the
three most common genetic causes of IRDs in their study populations
were ABCA4, USH2A, and RPGR (Pontikos et al., 2020; Stone
et al., 2017).
While genetic testing for IRDs is supported by large organizations
such as the American Academy of Ophthalmology as an important
component of clinical care, financial, and logistical barriers prevent
widespread genetic testing (Erwin, LaMaire, Espana, Eble, &
Dhar, 2020; Harrison et al., 2015; Stone et al., 2012). In order to over-
come this, several different genetic testing initiatives have been
developed by government programs, nonprofit foundations, and cor-
porations in which genetic testing through a CLIA-certified lab is avail-
able to patients at no cost to them. These programs include the
eyeGENE research study at the National Eye Institute, the Foundation
Fighting Blindness' My Retina Tracker Genetic Testing Study and
Open Access Genetic Testing Program, and Spark Therapeutics' ID
Your IRD Program.
The eyeGENE research study collected more than 6,000 samples
from 2006 to 2015 from patients and family members affected with
genetic eye diseases, including IRDs (Parrish et al., 2016). Through this
research initiative, patients provided DNA samples and phenotypic
data to a biorepository (Goetz, Reeves, Tumminia, & Brooks, 2012).
Genetic testing was performed on the samples and returned to
patients via their ordering providers. The samples and information in
the repository were made available to researchers through an applica-
tion process.
In 2017, Foundation Fighting Blindness, a nonprofit patient advo-
cacy organization for patients affected with IRDs, developed a genetic
testing study for patients enrolled in their patient registry: the My
Retina Tracker Registry (Shaberman & Durham, 2019). Patients pro-
vide demographic, family, and medical information for the registry and
get genetic testing at no cost through a CLIA-certified lab. Genetic
counseling is provided to all participants as part of the program. The
program expanded in October 2019, with the development with an
Open Access Genetic Testing Program, available to a greater number
of patients across the country (https://www.fightingblindness.org/
open-access-genetic-testing-program).
The ID your IRD program (https://www.eyewant2know.com/
idyourird), sponsored by Spark Therapeutics, the manufacturer of an
FDA-approved gene therapy treatment, serves as a similar genetic
testing program. The ID your IRD program provides genetic testing
at no cost to the patient through a CLIA-certified lab and genetic
counseling is available as well. While these programs have differ-
ences in testing panels used and data sharing, collectively, these
three programs have achieved a goal of making genetic testing avail-
able to thousands of patients affected with IRDs in the United
States, for whom genetic testing might otherwise have been cost-
prohibitive.
F IGURE 1 Genes known to cause
nonsyndromic retinitis pigmentosa
(https://sph.uth.edu/retnet/)
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2 | CURRENT DETECTION RATES
In the field of IRDs, currently available commercial panels and
research investigations have greatly enhanced the success of clini-
cians in identifying the genetic basis for disease. Large scale panels
are currently available in commercial testing labs, which vary by the
number of genes tested, methodology used, and diseases covered.
Deletions and duplications significantly contribute to disease burden,
being responsible for 7–9% of pathogenic variants in IRD patients
(Ellingford et al., 2018; Zampaglione et al., 2020). Multiple studies
have been conducted on large numbers of families (individual studies
ranging in size from 700 families to 2,420 families) affected with IRDs
in Ireland, Israel, England, and the United States. These studies show
an overall detection rate of 56–76% (Carss et al., 2017; Sharon
et al., 2020; Stone et al., 2017; Whelan et al., 2020). Clinical detection
rates may vary by diagnosis, as described by Carss et al, where detec-
tion rates varied from 29% in patients with cone dystrophy to 89% in
patients with LCA (Carss et al., 2017). Similarly, studies have also
shown that detection rates may vary based on age—with a higher
detection rate in individuals less than 50 years of age. (Shah
et al., 2020).
3 | DEVELOPMENT OF GENE-BASED
TREATMENTS AND TRIALS
The field of retinal genetics has proven to be a pioneer in the area of
gene therapy when a retinal degeneration was the first disease for
which a gene therapy treatment became FDA-approved. This therapy
for RPE65-associated retinal degeneration was developed by Spark
Therapeutics. Voretigene neparvovec-rzyl (Luxturna) was approved by
the FDA to treat patients affected with retinal degeneration due to
pathogenic variants in RPE65 in 2017, and the first patient was treated
in 2018 (Ciulla, Hussain, Berrocal, & Nagiel, 2020; Russell et al., 2017).
Several other gene-based treatments are currently in clinical trials,
including gene augmentation for CNGA3, CNGB3, CHM, and RPGR;
CRISPR gene editing for CEP290; and oligonucleotide therapy for
CEP290, USH2A, and RHO (Thompson et al., 2020). The development
of these gene-dependent treatments highlights the importance of
determining the specific genetic cause of disease in patients with IRDs.
4 | COMPLICATIONS THAT CAN EMERGE
WHEN ORDERING GENETIC TESTING
4.1 | Identification of unexpected syndromic
conditions in patients with isolated retinal dystrophy
There are several syndromes that cause disease in multiple organ sys-
tems in addition to the retina (Werdich, Place, & Pierce, 2014). In
some of these conditions, the extraocular features of disease are obvi-
ous prior to the onset of retinal findings. Two of the more common
syndromic retinal dystrophies are Usher Syndrome and Bardet-Biedl
Syndrome (BBS). Patients with Usher Syndrome type 1 and 2 have
congenital hearing loss and develop RP as a child or young adult. In
patients with BBS, the primary features are obesity, postaxial polydac-
tyly, renal disease, hypogonadism, learning disabilities, and RCD. Reti-
nal degeneration is present in more than 90% of these patients
(Forsythe & Beales, 2013). Although the diagnosis of BBS may not be
suspected until the retinal findings are diagnosed, one or more of the
extraocular features of this condition may be present from birth
and/or early childhood.
In other cases, the retinal findings may be the presenting sign, or
subclinical findings in other organ systems may be present but
unknown to the patient and provider. For example, in the juvenile form
of neuronal ceroid lipofuscinosis (Batten disease), the typical presenta-
tion is a rapidly progressing retinal dystrophy. The vision loss is
followed by cognitive decline and other neurodegenerative symptoms
(Adams, Mink, & University of Rochester Batten Center Study, 2013)
and is characterized by seizures. In cases such as these, as highlighted
in the case example below, genetic testing may identify a syndromic
retinal dystrophy in a case otherwise suspected to be nonsyndromic.
4.1.1 | Case example 1
A 6-year-old boy presented for an evaluation for macular dystrophy.
No developmental or health concerns were noted, and he was doing
well in school. Visual acuity was 20/50 in each eye. The electroretino-
gram (ERG) was abnormal, with rod responses reduced to 10% of nor-
mal and cone isolated responses approximately 40% of normal. On
fundus exam, he was noted to have macular atrophy in both eyes
(Figure 2). Genetic testing on a retinal dystrophy panel was per-
formed, and he was suspected to have a deletion in the CLN3 gene.
Further CNV analysis confirmed that he was homozygous for a 1-kb
deletion of the deletions 8–9 (estimated breakpoints chr16:
28498251–28497286; hg19) in the CLN3 gene. This deletion is the
most commonly identified pathogenic variant in individuals with
CLN3-related juvenile-onset Batten disease. Following the diagnosis,
the patient was referred to a multidisciplinary clinic for Batten disease,
and he continued to follow in our clinic as well. At the age of 9, his
visual acuity had progressed to hand motion vision in the right eye
and 20/2,800 in the left eye, which is legally blind, and he was receiv-
ing therapy for behavioral problems. Surprising and devastating diag-
noses such as this highlight the importance of pretest counseling for
patients undergoing large retinal dystrophy panels and specifically of
warning them that, even if their condition appears to be solely vision-
related, syndromic conditions are also tested on the panel and may be
identified.
4.2 | Challenges of inheritance counseling
The extreme genetic heterogeneity, multiple inheritance patterns, and
diverse phenotypic features of several IRDs can pose challenges for
providing accurate genetic counseling and recurrence risks prior to
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obtaining genetic testing. In the case of nonsyndromic RP, over
90 genes have been identified, which have autosomal dominant, auto-
somal recessive, X-linked, and mitochondrial forms of inheritance
(https://sph.uth.edu/retnet/). Some of these RP genes, including
BEST1, NR2E3, NRL, RHO, RP1, and RPE65 (Daiger, Bowne, &
Sullivan, 2014) may be associated with both autosomal dominant and
autosomal recessive patterns of inheritance (Figure 1). Several of the
retinal dystrophy genes may be associated not only with variable
inheritance patterns, but also with variable phenotypes. As an exam-
ple of this, the CRX gene may be associated with autosomal dominant
cone-rod dystrophy, autosomal dominant or autosomal recessive LCA,
and autosomal dominant RP (Sohocki et al., 1998). There has also
been a report of a family with a child affected with LCA with a homo-
zygous pathogenic variant in CRX, and her carrier parents manifested
milder late onset retinal abnormalities (Swaroop et al., 1999).
Pedigree analysis for determining the pattern of inheritance
within a family affected with RP is complicated by several factors. In
cases of simplex RP, in which no other cases of RP are identified in
the family, autosomal recessive inheritance is the most likely pattern
of inheritance; however, several studies have demonstrated that these
cases may actually be due to mutations in genes with X-linked or
autosomal dominant inheritance. In one study, 15% of isolated males
affected with RP and cone-rod dystrophies were found to have dis-
ease causing variants in the X-linked RPGR gene (Branham
et al., 2012). It was not determined if these males harbored de novo
mutations or if the variant was passed through unaffected female car-
riers. Churchill et al. (2013) found that 8.5% of families originally
thought to have an autosomal dominant pattern of inheritance were
subsequently found to have disease causing variants in the X-linked
genes RPGR or RP2. X-linked inheritance should be considered as a
possibility in families with more than one generation of individuals
affected but where male-to-male transmission is lacking, especially if
males are more severely affected than females or if females have
asymmetric disease (Churchill et al., 2013). In IRD genes with autoso-
mal dominant inheritance, reduced penetrance can be seen, making
pedigree interpretation of these families difficult as well (Rivolta
et al., 2006). In particular, pathogenic variants in the splicing factor
PRPF31 are associated with nonpenetrance the majority of families
(Rose & Bhattacharya, 2016). Furthermore, consanguinity or high
carrier rates can create the appearance of dominance in a pedigree
when the pattern of inheritance is actually recessive—sometimes ter-
med “pseudo-dominance.” Pseudo-dominant inheritance has been
reported in several nonconsanguineous families affected with ABCA4-
related retinal dystrophies such as Stargardt disease and cone-rod
dystrophy due to the relatively high carrier rate of pathogenic variants
in the ABCA4 gene (Huckfeldt, East, Stone, & Sohn, 2016; Maugeri
et al., 2000) .
Further complicating inheritance counseling of patients with IRDs
is the fact that there may be more than one genetic cause of disease
within a family. Typically, it would be assumed that multiple members
of a family affected with retinal degeneration would have the same
genetic cause of disease. However, there have been reports of more
than one genetic cause of retinal degeneration being identified within
a family (Birtel et al., 2020; Jones et al., 2017). This situation can com-
plicate inheritance counseling and selection of the appropriate genetic
test for individuals in these families.
4.2.1 | Case example 2
A 9-year-old boy presented to clinic and was diagnosed with RP
based on findings of nearly nonrecordable rod and cone ERG
responses, elevated dark adaptation thresholds, and peripheral pig-
mentation in both eyes. At the time of diagnosis, he was believed to
be an isolated case of disease. Subsequently, his mother reported
night vision loss just before the age of 40. She was found to have
significantly reduced rod and cone function. Best corrected visual
acuity was 20/25 in her right eye and 20/30 in her left eye when
examined at the age of 40. She also had a ring scotoma on visual
field testing, and fundus exam showed diffuse retinal atrophy
(Figure 3a,b). She subsequently experienced a progressive loss of
visual acuity and visual field (Figure 3b). At the age of 45, her visual
acuity had progressed to 20/50 in the right eye and 20/100 in the
left. Based on the pedigree (Figure 3c), an autosomal dominant pattern
of inheritance might have been expected, but the mother and son were
found to have a pathogenic missense variant (p.Phe130Cys) in the
X-linked RPGR gene, which is believed to be the cause of disease in
the family.
F IGURE 2 Fundus images from the
left and right eyes showing macular
atrophy in a 6-year-old boy with Batten
disease
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4.3 | Importance of phenotyping
Since inherited retinal dystrophies are genotypically and phenotypi-
cally diverse, with symptoms overlapping between several different
conditions, detailed phenotypic information can be important to
appropriately guide genetic testing. For example, congenital nystag-
mus can be seen in several different types of retinal dystrophy, which
can have very different prognoses. Retinal dystrophies included in the
differential diagnosis for a patient with congenital nystagmus could be
LCA, achromatopsia, and congenital stationary night blindness
(Papageorgiou, McLean, & Gottlob, 2014). However, since these con-
ditions represent distinct disease categories, they may not be tested
on the same genetic panel. Further clinical evaluation, such as an ERG,
which may only be available in retinal dystrophy clinics, may be
warranted to help clarify the clinical diagnosis. This information is
essential in the determination of which genetic test is most appropri-
ate for such patients and in the interpretation of genetic test results.
In many cases, testing for a broader retinal dystrophy may assist the
geneticist in navigating the diverse phenotypic landscape of these
diseases.
4.3.1 | Case example 3
A 10-month-old boy was referred to the IRD clinic for a possible diag-
nosis of LCA based on his history of nystagmus and decreased vision.
He was born from a triplet pregnancy, with no history of vision loss in
his siblings. His nystagmus was noted at 2 months of age, and his par-
ents reported that he did not follow large objects. In clinic, ERG test-
ing demonstrated near normal rod functioning and near
nonrecordable cone functioning. Therefore, the clinical exam was
actually consistent with a cone dystrophy such as achromatopsia. This
was confirmed with genetic testing, which identified two pathogenic
variants in the CNGB3 gene, consistent with this diagnosis. If genetic
testing had been ordered for a targeted LCA panel prior without clini-
cal testing to fully evaluate the cause of his vision, this gene would
not have been evaluated, and the clinical and genetic diagnosis would
have remained unknown for this patient.
5 | CONCLUSION
Since the identification of the first retinal dystrophy gene in 1990, signifi-
cant advances have been made in the study of the genetic basis for
inherited retinal diseases. Advances in genetic diagnostic testing have
allowed the field to progress to the point where the genetic basis of dis-
ease is identified for 56–76% of patients when tested on large NGS
panels. The importance of genetic testing is highlighted by the genotypic
complexity of this group of conditions, which can only be clarified
through testing. This complexity is evidenced not only by the sheer num-
ber of genes that have been identified, but also by the wide phenotypic
variability and the significant genetic heterogeneity for many of the con-
ditions, which can result in the misinterpretation of inheritance pattern
when predicted based only on family history information. In addition,
with the development of therapeutic FDA-approved treatments and
gene therapy clinical trials, genetic testing results have become essential
for the treatment andmanagement of these eye conditions.
F IGURE 3 (a) Pedigree from family showing what was believed to
be an autosomal dominant pattern of inheritance prior to genetic
testing, which identified a mutation in an X-linked gene. (b) Fundus
images from the mother of proband showing diffuse retinal atrophy in
the left and right eyes. (c) Goldmann visual field tests from the mother
of proband showing a partial ring scotoma in the left and right eyes at
the age of 40 (bottom two images) and 45 (top two images). Further
constriction of the central visual field and peripheral islands of vision
are found to remain after this 5-year period of time
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Genetic testing has traditionally been performed in the clinical
genetics setting, but as it becomes more common in different medical
specialties, such as ophthalmology, appropriate integration of this
testing becomes necessary. Some IRD clinics have both ophthalmolo-
gists trained in IRD and genetic counselors and/or clinical geneticists
who work together as a team. However, many ophthalmologists do
not have genetic resources available. While ophthalmologists have
extensive training in the diagnosis and ophthalmic management of
these conditions, they may be less experienced with the nuances
associated with ordering genetic testing, interpreting these genetic
test results, and genetic counseling of patients affected with inherited
retinal conditions. On the other hand, clinical geneticists and genetic
counselors would not be able to perform extensive ophthalmic
phenotyping in their genetics clinics. As evidenced by the case exam-
ples here, there are challenges that exist in selecting the appropriate
test for patients, understanding the inheritance of inherited retinal
dystrophies, and preparing for unexpected genetic testing results with
which genetic and ophthalmic providers must be familiar in order to
provide appropriate comprehensive clinical care for these patients.
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